Compare SpaceX (SPCX) vs 10X Genomics Inc (TXG) Price & Performance

SPCX trades at $153.47, up 3.73% today, with strong analyst support (90% buy ratings) and a $227.22 consensus price target suggesting 48% upside. Despite negative profitability metrics, the company shows robust revenue growth and significant cash flow generation. Technical indicators show a bullish trend with key support at $147 and resistance at $157. Recent news highlights insider share unlocks creating temporary selling pressure but strong institutional interest.

The outlook remains positive given SpaceX's innovation pipeline and market leadership, though investors face risks from high valuation multiples, ongoing losses, and competitive pressures. The stock's premium valuation requires continued execution on growth targets to justify current levels.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.